NVAX - NOVAVAX INC
IEX Last Trade
8.31
-0.100 -1.203%
Share volume: 24,098
Last Updated: Fri 27 Dec 2024 05:29:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$8.41
-0.10
-1.19%
Fundamental analysis
31%
Profitability
36%
Dept financing
25%
Liquidity
21%
Performance
30%
Performance
5 Days
-1.50%
1 Month
-2.74%
3 Months
-29.93%
6 Months
-35.09%
1 Year
68.51%
2 Year
-3.95%
Key data
Stock price
$8.31
DAY RANGE
$8.19 - $8.66
52 WEEK RANGE
$3.80 - $23.86
52 WEEK CHANGE
$73.32
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Stanley C. Erck
Region: US
Website: novavax.com
Employees: 1,990
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: novavax.com
Employees: 1,990
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Novavax, Inc. focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial. NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate, is in Phase 3 clinical trial. ResVax is a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
Recent news